Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography

Rodrigo, M.J. ; Pérez Del Palomar, A. (Universidad de Zaragoza) ; Montolío, A. (Universidad de Zaragoza) ; Mendez-Martinez, S. (Universidad de Zaragoza) ; Subias, M. ; Cardiel, M.J. (Universidad de Zaragoza) ; Martinez-Rincon, T. ; Cegoñino, J. (Universidad de Zaragoza) ; Fraile, J.M. ; Vispe, E. ; Mayoral, J.A. (Universidad de Zaragoza) ; Polo, V. (Universidad de Zaragoza) ; Garcia-Martin, E. (Universidad de Zaragoza)

Resumen: Intravitreal injection is the gold standard therapeutic option for posterior segment patholo-gies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF.

Idioma: Inglés

DOI: 10.3390/pharmaceutics13020217

Año: 2021

Publicado en: Pharmaceutics 13, 2 (2021), 217 [16 pp]
ISSN: 1999-4923

Factor impacto JCR: 6.525 (2021)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 39 / 279 = 0.14 (2021) - Q1 - T1

Factor impacto CITESCORE: 6.0 - Pharmacology, Toxicology and Pharmaceutics (Q2)

Factor impacto SCIMAGO: 0.922 - Pharmaceutical Science (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/M17-00213
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946
Financiación: info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Química Orgánica (Dpto. Química Orgánica)
Área (Departamento): Área Oftalmología (Dpto. Cirugía)
Área (Departamento): Área Mec.Med.Cont. y Teor.Est. (Dpto. Ingeniería Mecánica)
Área (Departamento): Área Anatomía Patológica (Dpto. Cirugía)